Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073880 | 1.00 | MAPK14 (0.40) | MAPK14CHRM1CCR2KCNH2IP6K1 | |
| SCHEMBL20073881 | 0.94 | MAPK14 (0.46) | MAPK14CHRM1CCR2KCNH2 | |
| SCHEMBL29709316 | 0.94 | MAPK14 (0.46) | MAPK14CHRM1CCR2KCNH2 | |
| SCHEMBL20073893 | 0.91 | IP6K1 (0.40) | MAPK14CHRM1IP6K1 | |
| SCHEMBL20073886 | 0.90 | NQO2 (0.40) | MAPK14CHRM1 | |
| SCHEMBL20073879 | 0.89 | CHRM1 (0.45) | MAPK14CHRM1 | |
| SCHEMBL29709353 | 0.89 | CHRM1 (0.45) | MAPK14CHRM1 | |
| SCHEMBL20073883 | 0.89 | CHRM1 (0.45) | MAPK14CHRM1 | |
| SCHEMBL29709346 | 0.89 | CHRM1 (0.45) | MAPK14CHRM1 | |
| SCHEMBL23778304 | 0.89 | MAPK14 (0.43) | MAPK14CHRM1CCR2KCNH2IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | MAPK14 4186/4885CHRM1 1/4885CCR2 209/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | MAPK14 4186/4885CHRM1 1/4885CCR2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.